Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia

被引：46

作者：

Jaglowski, Samantha M. ^{[1
]}

Ruppert, Amy S. ^{[1
]}

Heerema, Nyla A. ^{[2
]}

Bingman, Anissa ^{[1
]}

Flynn, Joseph M. ^{[1
]}

Grever, Michael R. ^{[1
]}

Jones, Jeffrey A. ^{[1
]}

Elder, Patrick ^{[1
]}

Devine, Steven M. ^{[1
]}

Byrd, John C. ^{[1
,3
]}

Andritsos, Leslie A. ^{[1
]}

机构：

[1] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA

[2] Ohio State Univ, Dept Pathol, Cytogenet Div, Columbus, OH 43210 USA

[3] Ohio State Univ, Div Med Chem, Dept Pharm, Columbus, OH 43210 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷 / 01期

关键词：

chronic lymphocytic leukaemia; transplant; fluorescent insitu hybridization; metaphase cytogenetics; conditioning; STEM-CELL TRANSPLANTATION; RITUXIMAB; IMPACT; GENE;

D O I：

10.1111/j.1365-2141.2012.09239.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Complex karyotype (CK) on metaphase cytogenetics discriminates poor outcome in chronic lymphocytic leukaemia (CLL) patients undergoing salvage treatment; we hypothesized that it might provide prognostic information for patients undergoing allogeneic stem cell transplant. Fifty-one CLL patients were analysed following transplant; 18-month overall survival (OS), event-free survival (EFS) and cumulative incidence of progression estimates were 35%, 14% and 63%, respectively, in patients with CK (n=19) versus 83%, 68% and 29% in patients without (n=32) (P=0.0001, P=0.0001, and P=0.02). In patients with high-risk interphase cytogenetics, CK remained predictive of worse OS (P=0.02) and EFS (P=0.009). These findings support further evaluation of metaphase karyotype in transplant risk assessment.

引用

页码：82 / 87

页数：6

共 15 条

[1] Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy [J].

Byrd, JC ;

Gribben, JG ;

Peterson, BL ;

Grever, MR ;

Lozanski, G ;

Lucas, DM ;

Lampson, B ;

Larson, RA ;

Caligiuri, MA ;

Heerema, NA .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :437-443

[2] Genomic aberrations and survival in chronic lymphocytic leukemia. [J].

Döhner, H ;

Stilgenbauer, S ;

Benner, A ;

Leupolt, E ;

Kröber, A ;

Bullinger, L ;

Döhner, K ;

Bentz, M ;

Lichter, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916

[3] Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning [J].

Dreger, P ;

Brand, R ;

Hansz, J ;

Milligan, D ;

Corradini, P ;

Finke, J ;

Deliliers, GL ;

Martino, R ;

Russell, N ;

van Biezen, A ;

Michallet, M ;

Niederwieser, D .

LEUKEMIA, 2003, 17 (05) :841-848

[4] Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial [J].

Dreger, Peter ;

Doehner, Hartmut ;

Ritgen, Matthias ;

Boettcher, Sebastian ;

Busch, Raymonde ;

Dietrich, Sascha ;

Bunjes, Donald ;

Cohen, Sandra ;

Schubert, Joerg ;

Hegenbart, Ute ;

Beelen, Dietrich ;

Zeis, Matthias ;

Stadler, Michael ;

Hasenkamp, Justin ;

Uharek, Lutz ;

Scheid, Christof ;

Humpe, Andreas ;

Zenz, Thorsten ;

Winkler, Dirk ;

Hallek, Michael ;

Kneba, Michael ;

Schmitz, Norbert ;

Stilgenbauer, Stephan .

BLOOD, 2010, 116 (14) :2438-2447

[5] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[6] A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].

GRAY, RJ .

ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154

[7] Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival [J].

Khouri, IF ;

Lee, MS ;

Saliba, RM ;

Andersson, B ;

Anderlini, P ;

Couriel, D ;

Hosing, C ;

Giralt, S ;

Korbling, M ;

McMannis, J ;

Keating, MJ ;

Champlin, RE .

EXPERIMENTAL HEMATOLOGY, 2004, 32 (01) :28-35

[8] Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia [J].

Moreno, C ;

Villamor, N ;

Colomer, D ;

Esteve, J ;

Martino, R ;

Nomdedéu, J ;

Bosch, F ;

López-Guillermo, A ;

Campo, E ;

Sierra, J ;

Montserrat, E .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3433-3438

[9] Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate [J].

Muthusamy, Natarajan ;

Breidenbach, Heather ;

Andritsos, Leslie ;

Flynn, Joseph ;

Jones, Jeffrey ;

Ramanunni, Asha ;

Mo, Xiaokui ;

Jarjoura, David ;

Byrd, John C. ;

Heerema, Nyla A. .

CANCER GENETICS, 2011, 204 (02) :77-83

[10] Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia [J].

Ritgen, M ;

Lange, A ;

Stilgenbauer, S ;

Döhner, H ;

Bretscher, C ;

Bosse, H ;

Stuhr, A ;

Kneba, M ;

Dreger, P .

BLOOD, 2003, 101 (05) :2049-2053

← 1 2 →